Some images has been designed using resources from Unsplash & Pixabay & Pexels & Freepik and some icons from Flaticon
跳到主要內容
:::
Physican
:::

Chun-Chin Chang, M.D.

Chun-Chun Chang, M.D., PhD, FACC, FESC
Education:
  • National Yang-Ming University
    Institute of Clinical Medicine, National Yang-Ming University
.................................................................................................................................................................................
Current Positions​:
  • Attending physician, Department of internal medicine, Dividion of cardiology, Taipei Veterans General Hospital
...............................................................................................................................................................................................
Faculty:
  • Asistant Professor of medicine, National Yang Ming Chiao Tung  University
...............................................................................................................................................................................................

Experience

  • Resident physician, Department of Medicine, Taipei Veterans General Hospital
  • Fellow in Division of Cardiology, Taipei Veterans General Hospital
  • Visiting Scholar of Division of Cardiology, Kobe University Hospital, Japan                    
  • Attending physician in Division of Cardiology, Taipei Veterans General Hospital, Tao-Yuan branch, Tao-Yuan, Taiwan.
...............................................................................................................................................................................................
Specialist Certificate:
  • License of physician, Taiwan                            
  • Specialist of Internal Medicine
  • Specialist of Cardiovascular Medicine
  • Specialist of Interventional Cardiology
  • Specialist of Critical Care
..............................................................................................................................................................................................
Medical Expertise​:
  • Cardiovascular disease
  • Cardiac catheterization and intervention
  • Peripheral arterial intervention
...............................................................................................................................................................................................
E-mail
..............................................................................................................................................................................................
Important Publication:
  1. Zaman A, de Winter RJ, Kogame N, Chang CC, Modolo R, Spitzer E, Tonino P, Hofma S, Zurakowski A, Smits PC, Prokopczuk J, Moreno R, Choudhury A, Petrov  I, Cequier A, Kukreja N, Hoye A, Iniguez A, Ungi I, Serra A, Gil RJ, Walsh S,  Tonev G, Mathur A, Merkely B, Colombo A, Ijsselmuiden S, Soliman O, Kaul U, Onuma Y, Serruys PW; TALENT trial investigators.  Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial.  Lancet.  2019;393(10175):987-997.
  2. Chang CC, Kogame N, Onuma Y, Byrne RA, Capodanno D, Windecker S, Morel MA, Cutlip DE, Krucoff MW, Stone GW,  Lansky AJ, Mehran R, Spitzer E, Fraser  AG, Baumbach A, Serruys PW. Defining Device Success for Percutaneous Coronary  Intervention Trials: A Position Statement from the European Association of    Percutaneous Cardiovascular Interventions of the European Society of Cardiology. EuroIntervention. 2019; pii: EIJ-D-19-00552
  3. van Geuns RJ, Chang CC, McEntegart MB, Merkulov E, Kretov E, Lesiak M, O'Kane P, Hanratty CG, Bressollette E, Silvestri M, Wlodarczak A, Barragan P, Anderson R, Protopopov A, Peace A, Menown I, Rocchiccioli P, Onuma Y, Oldroyd KG. Bioabsorbable-polymer drug-eluting stents with 4-month dual antiplatelet therapy versus durable-polymer drug-eluting stents with 12-month dual antiplatelet therapy in patients with left main coronary artery disease: the IDEAL-LM randomized trial. EuroIntervention. 2022;17(18):1467-1476.
  4. Chang CC, Veen KM, Hahn RT, Bogers AJJC, Latib A, Oei FBS, Abdelghani M,  Modolo R, Ho SY,  Abdel-Wahab M, Fattouch K, Bosmans J, Caliskan K, Taramasso M, Serruys PW, Bax JJ, van Mieghem NMDA,  Takkenberg JJM, Lurz P, Modine T, Soliman O. Uncertainties and challenges in surgical and transcatheter tricuspid  valve  therapy: a state-of-the-art expert review.  Eur Heart J. 2019; pii: ehz614.
  5. Chang CC, Lee YH, Chuang MJ, Hsueh CH, Lu YW, Tsai YL, Chou RH, Wu CH, Lu TM, Huang PH, Lin SJ, van Geuns RJ. Agreement Between Invasive Wire-based and Angiography-Based Vessel Fractional Flow Reserve Assessment on Intermediate Coronary Stenoses. Front Cardiovasc Med. 2021;8:707454.

限於篇幅,以上謹為代表著作

Last Modified:

回到最上